Lisata acquires Marea and signs $225 million financing agreement
Lisata ($LSTA) Therapeutics acquired Marea Therapeutics in a stock-for-stock transaction and signed a concurrent agreement for approximately $225 million in gross private-placement proceeds. The financing involves non-voting convertible preferred shares and is expected to fund operations into 2028. The acquisition is complete, while the financing announcement describes an agreement rather than confirming that all proceeds have been received. The expanded pipeline centers on MAR001/005 for severe
0